Nanosynth Group Plc
0.0025 (1.33%)
Share Name Share Symbol Market Type Share ISIN Share Description
Nanosynth Group Plc LSE:NNN London Ordinary Share GB00BFX0ZN92 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0025 1.33% 0.19 0.18 0.20 0.19 0.19 0.19 1,312,829 09:41:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Technology Hardware & Equipment 0.2 -2.4 -0.1 - 4

Nanosynth Group PLC Corporate and Commercial Update

17/01/2023 7:00am

UK Regulatory (RNS & others)

Nanosynth (LSE:NNN)
Historical Stock Chart

From Dec 2022 to Mar 2023

Click Here for more Nanosynth Charts.


RNS Number : 9066M

Nanosynth Group PLC

17 January 2023

Nanosynth Group Plc

("Nanosynth", "Group" or the "Company")

Corporate and Commercial Update

nanosynth group plc, the AIM quoted company specialising in the synthesis and application of nanoparticles to create new and improve existing products, is pleased to provide the following corporate and commercial update.

Company Update

2022 was a year of substantial progress for the Group in which we have successfully transitioned from acquiring a university spin-out to a business with some excellent, viable commercial opportunities in fast-growing markets.

The Board is now firmly of the view that the Group has clear direction and a detailed execution plan.

Supporting our strategy and furthering our ability to deliver our goals, the Board welcomes the interest and investment from Lanstead and Oval X as new investors in recent months which have provided working capital and supported our capital expenditure needs.

In order to provide us with the laboratory facilities needed to grow, we have agreed to work with Bio City in Nottingham to develop the existing space to create dedicated production facilities for the agritech market, cosmetics market and general technology. This will provide improved and enlarged wet and dry laboratory facilities, enabling further R&D, with greater warehousing, storage and office space. Work on the new facilities is due to commence during the first quarter of 2023. We are pleased that the Company will be maintaining its roots in the city where P2F was founded and where ibuprofen was first discovered.

With the increased opportunities that are now being progressed, some of which are outlined below, production facilities are expected to be scaled up to meet future demand and enable dedicated nano-production. This is intended to be achieved through the manufacture of nano-material reactors of various size and suitable for both small and large scale production, allowing for a shift work pattern and short lead-times. Design and testing of reactors is currently being finalised and we hope to commission the first of these new reactors during the first half of the year.

The Board has focused Company efforts towards entering and establishing itself in seven strategic vertical markets having an aggregate value of in excess of GBP3.6 billion. Our objective has been to seek potential market sector leading clients and to demonstrate to them the potential competitive advantages of implementing our nanotechnology projects, including the attractive returns on investment that we consider to be achievable. This process has enabled us to very quickly identify our most likely project partners.

Coupled with this, the Board has strengthened the Company's intellectual property portfolio, beyond the two pre-existing licenced process patents, filing two new patents in the areas of "Nanoparticles for the use in anti-pathogenic applications" (WO2022084685A1) and "Soluble nanoparticles for the use in cosmetic and sunscreen applications" (GB202118048DO). The Company's research and development across its seven chosen vertical markets has led to additional intellectual property being identified which we expect to file in due course.

Our management team has been significantly strengthened over the last year, with a new Chief Technical Officer Imad Naasani joining P2F on 1(st) September 2022. Imad was based in Japan and the USA and brings extensive Nanotechnology experience to the Group as well as the proven ability to commercialise the science. Supported by our dedicated project management experience from the cosmetic industry, the appointment provides us with a new level of professionalism. Combined with the increased resources and skills within the labs outlined above we now believe we are well placed to deliver the necessary products for the future.

We are also in the process of updating some of our brand names (in particular P2F which is to be renamed Nanovate) and adding new brands to the Nanosynth Group.

Commercial update


 --   The joint development project with a household name wellness 
       company progressed well during the later half of 2022, 
       and the first of three batches of designed ingredients 
       are being shipped in January 2023. Production of a second 
       work package is due to commence imminently. This is an 
       exciting commercial opportunity with a global company 
       where legislation is driving the need for change. We recently 
       obtained UK REACH registration for ZnO for volumes up 
       to 100 tonnes per year to enable potential future production 
       for this wellness company. 
 --   In response to a UK and European Commission decision to 
       ban therapeutic use of zinc oxide (to reduce diarrhoea 
       in post weaning piglets) from June 2022, a global branded 
       animal feed provider has completed national and international 
       trials with a new Nanovatepiglet feed supplement. The 
       results of the trials show that the new nano product may 
       offer a viable alternative to the now banned zinc oxide 
       to UK and EU farmers. Nanovate is discussing possible 
       commercial collaboration with this potential partner company 
       during the first quarter of 2023. Nanovate will also be 
       seeking to supply feed for a wide range of animals via 
       key strategic partners and feed manufactures across the 
 --   Initial trials with a household international paint company 
       were completed during the year and have shown initial 
       success and enabled the Company to create an antipathogenic 
       paint designed to kill Streptococcus (the cause of scarlet 
       fever), Methicillin-resistant Staphylococcus aureus (MRSA), 
       E.coli and Pseudomonas aeruginosa bacteria on contact 
       and prevents further bacterial growth. The Company's patented 
       copper nanoparticles were incorporated into a commercial 
       white emulsion paint to create the antipathogenic paint 
       - with no observed discolouration or reduced performance 
       effects of the applied paint. Further work is required 
       with a suitable partner to commercialise the offering 
       and the Company is seeking partners outside of China. 
 --   P2F is in final negotiations with a large farming company 
       for a project within the agriculture field, where we will 
       be looking to use our technology to enhance yields and 
       tackle other factors such as hidden hunger (where the 
       quality of food people eat does not meet their nutritional 
       requirements). We expect this project, once the agreement 
       is finalised, to begin in Q2 2023. 
 --   The Company is in final negotiations within the seed coating 
       space and is hoping to begin an R&D project by mid 2023. 
 --   A global blue chip company is expected to begin to evaluate 
       our minerals in H1 of 2023 with a view to starting a project 
       in cosmetics if evaluation is successful. 
 --   A large domestic plant food and fertiliser manufacturer 
       is expected to commence trials with our nano minerals 
       to enhance an existing product line with a view to move 
       straight to commercialisation. 
 --   We are continuing to look for companies within the seven 
       identified key verticals with whom to undertake projects. 

P2F product launch

 --   During 2022, the Company carried out in-house trials on 
       various plants to determine how to improve and accelerate 
       their growth via the use of nano technology. The trials 
       have shown great results and the Company will be launching 
       a Nano shot for the hydroponics market in the first quarter 
       of 2023 called the Atomic Nano. Further Nano Shots are 
       expected to be released later in the year for plants, 
       vegetables and fruit. Immediate interest and engagement 
       of a major fruit and vegetable supplier has been forthcoming 
       and we expect this to result in a joint development for 
       bespoke fertilizer products in due course. 

GB Nano

 --   GB Nano has been established to become our in-house online 
       ecommerce store and to be the go-to for clients to source 
       Nano ingredients. Our intention is to list 90 plus products 
       over the next two years with an initial launch of 12 that 
       will be fully tested and regulated. A growing list of 
       metal oxides nanoparticles with functional surface chemistries 
       is being productised and made off-the-shelf to suit a 
       wide range of applications including, life science, cosmetics, 
       healthcare, medical device, electronics, plastic industry, 
       energy storage, filtration, and numerous other niche applications. 
       The off-the-shelf store will enable clients who have missed 
       out on some of the key license projects within Nanovate 
       to continue to have access to nano ingredients to undertake 
       their own developments. 
 --   The store is already attracting interest from major household 
       named cosmetic and research and development companies. 

Virosynth Joint Venture Status

 --   Manufacturing 
             *    P2F has formulated nano copper ink and applied it to 
                  polypropylene and polyester media 
             *    6,000 litres of ink have been produced to meet 
                  initial expected demand as marketing the product 
             *    A faster in line testing process is being developed 
                  to support scale up 
 --   Registration 
             *    P2F has been granted UK REACH registration for CuO 
                  for volumes up to 100 tonnes per year 
 --   Client development and testing 
             *    Leaching testing for environmental purposes under BS 
                  EN 12457 has been conducted with positive results - 
                  polypropylene and polyester media are classified as 
                  non-hazardous articles as they contain 
             *    Leachate data of both media suggests they may be 
                  classified as Inert waste or stable non-reactive 
                  hazardous waste (this means the media may be 
                  deposited in landfill but not mixed with 
                  biodegradable landfill cells). Both wastes are 
                  suitable for incineration 
             *    Process improvements have led to OCT imagery that 
                  shows improved CuO ink penetration within the media 
                  compared initial proof of concept. 
 --   Commercial agreements 
             *    Supply agreements have been prepared to issue to 
                  prospective clients on a nonexclusive basis 
 --   Product launch 
             *    Nanosynth/Virosynth will exhibit at the Filtech show 
                  in Cologne in February where it will launch our new 
                  product offering to a worldwide market. We will be 
                  presenting the novel technology in a series of 
                  presentations and events and currently 400 plus 
                  organisations are being invited to come and meet us 
                  during the event. 


The Company remains committed to establishing partnerships and distribution outlets globally. We are currently working with:

 --   An agent to promote our copper coated technology to be 
       applied to surgical gloves for the healthcare industry. 
 --   An agent to promote our nanotechnology within the animal 
       health, paint, rubber manufacturing and paint industries. 

Fast Food Sector Opportunity

Through a long-established relationship, the Company has had the opportunity to apply its capabilities to solve a fundamental problem within the fast food industry. Restaurants and fast-food chains have been seeking a solution to the problem of retaining heat in food being delivered from a kitchen to the customer, whilst not degrading the quality of the product. Nanosynth is working confidentially with a global branded fast-food provider to reduce the temperature loss over a 20-minute period. To-date trials have managed to achieve a 13 degree positive saving on existing solutions, being only one degree short of the targeted goal. Further trials are underway, and the team remain excited and positive about the opportunity, albeit it is early days. Once the target has been reached and verified by the client, Nanosynth will look to offer the technical solution and ingredients to packaging manufacturers globally for their clients.

Future outlook and plans

The Board remain positive and excited at the opportunities that have been developed over the last year, albeit there is still a lot of hard work to be undertaken to get the Company to profitability. As such the Board wants to thank all the team for their commitment and support now and in the future. Market conditions to date have not leant themselves to explore an M&A strategy for the business but working with household brand named clients will open up opportunities for partnerships and more.

Mark Duffin said "2022 was a year of substantial progress and we are excited by the opportunities that have been developed. The Board appreciates the frustration of shareholders wanting a constant news flow of RNS announcements, but the Company can only update the market collectively at the same time and not answer individual specific questions from shareholders. The Company's current transition and development mean newsflow opportunities will be limited until we have established the Group as the go-to provider in our various chosen markets. We will however keep shareholders updated of all material developments in our various projects during 2023."

MAR Wording

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service ('RIS'), this inside is now considered to be in the public domain.


nanosynth group plc                Via IFC 
 Mark Duffin, CEO 
S P Angel Corporate Finance LLP 
 Stuart Gledhill                   +44 (0)20 3470 
 Kasia Brzozowska                   0470 
IFC Advisory Limited 
 Graham Herring 
 Zach Cohen                        +44 20 (0) 3934 6630 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

January 17, 2023 02:00 ET (07:00 GMT)

1 Year Nanosynth Chart

1 Year Nanosynth Chart

1 Month Nanosynth Chart

1 Month Nanosynth Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20230328 10:22:16